NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.00+₹41.00 (+2.33%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · INDOCO.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:06 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Indoco Remedies Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Indoco Remedies Limited’s forward annual dividend is ₹0.20 per share, paid annual. The forward yield is 0.1% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Indoco Remedies Limited’s next earnings report is currently expected on Jan 26, 2027, with estimated earnings per share of ₹2.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Indoco Remedies Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Jul 21, 2025 | -₹3.94-31.33% vs estimate | ₹4.29B-5.75% vs estimate |
|---|
| Q4 2025 | May 22, 2025 | -₹4.48-24.44% vs estimate | ₹3.90B+1.52% vs estimate |
|---|
| Q3 2025 | Jan 21, 2025 | -₹3.05-103.33% vs estimate | ₹4.11B+0.09% vs estimate |
|---|
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.00+₹41.00 (+2.33%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹9,736.00+₹72.00 (+0.75%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹178.23-₹6.70 (-3.62%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 20.43% below the high.
₹1,768.00-₹44.80 (-2.47%)
Evonile Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 31.71% below the high.
₹636.45-₹18.80 (-2.87%)
Solara Active Pharma Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 17.77% below the high.
₹213.28+₹8.88 (+4.34%)
Hikal Limited’s quoted price sits in the upper half of its reported 52-week range, 18.28% below the high.
₹87.66-₹1.65 (-1.85%)
Alembic Limited’s quoted price sits in the lower half of its reported 52-week range, 25.54% below the high.
